Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) stimulate the incretin system and lower glycaemic parameters in type 2 diabetes mellitus (T2DM). This analysis of clinical studies of up to 3years evaluated the safety of albiglutide, a GLP-1 RA, in people with T2DM.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Diabetes Res. Clin. Pract.

Title: Diabetes research and clinical practice

Publisher: Elsevier BV

ISSN (Electronic): 1872-8227

ISSN (Print): 0168-8227

Publication date (Electronic): Apr 2017

Volume: 126

Affiliations

[1 ] Department of Clinical Services Division of Medicine, Lund University, Lund, Sweden. Electronic address: Bo.Ahren@med.lu.se.

[2 ] Pharma Research & Development, GlaxoSmithKline, Collegeville, PA, USA. Electronic address: molly.c.carr@gsk.com.

[3 ] Pharma Research & Development, GlaxoSmithKline, Collegeville, PA, USA. Electronic address: Karen.J.Murphy@gsk.com.

[4 ] PPD, Inc, Morrisville, NC, USA. Electronic address: christopher.perkins@ppdi.com.

[5 ] Department of Medicine, Division of Endocrinology, Creighton University, Omaha, NE, USA. Electronic address: rendell@asndi.com.

[6 ] Pharma Research & Development, GlaxoSmithKline, Upper Merion, PA, USA. Electronic address: jasonmallory@hotmail.com.

[7 ] Pharma Research & Development, R&D Projects Clinical Platforms, PCPS Qsci Clinical Statistics, Research Triangle Park, Durham, NC, USA. Electronic address: Tim.Wilson@parexel.com.

[8 ] Pharma Research & Development, GlaxoSmithKline, Upper Merion, PA, USA. Electronic address: Susan.l.johnon@pfizer.com.

Article

Publisher Item ID: S0168-8227(16)30730-6

DOI: 10.1016/j.diabres.2017.02.017

PubMed ID: 28284167

SO-VID: faa5dfed-c77a-46a1-8821-4fd8a9b568e4

History

Keywords: Long-term safety,Incretins,Glucagon-like peptide-1,Diabetes mellitus

Data availability:

Keywords: Long-term safety, Incretins, Glucagon-like peptide-1, Diabetes mellitus

Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.

Read this article at

Abstract

Related collections

Core Readings in Statistical Mediation Analysis

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 144

Cited by 6